Annual EBITDA
-$77.65 M
-$10.47 M-15.58%
December 31, 2023
Summary
- As of February 24, 2025, DSGN annual EBITDA is -$77.65 million, with the most recent change of -$10.47 million (-15.58%) on December 31, 2023.
- During the last 3 years, DSGN annual EBITDA has fallen by -$69.33 million (-832.77%).
- DSGN annual EBITDA is now -3969.86% below its all-time high of -$1.91 million, reached on December 31, 2019.
Performance
DSGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$16.09 M
-$1.20 M-8.06%
September 30, 2024
Summary
- As of February 24, 2025, DSGN quarterly EBITDA is -$16.09 million, with the most recent change of -$1.20 million (-8.06%) on September 30, 2024.
- Over the past year, DSGN quarterly EBITDA has stayed the same.
- DSGN quarterly EBITDA is now -2483.15% below its all-time high of -$623.00 thousand, reached on March 31, 2020.
Performance
DSGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$60.23 M
+$2.59 M+4.13%
September 30, 2024
Summary
- As of February 24, 2025, DSGN TTM EBITDA is -$60.23 million, with the most recent change of +$2.59 million (+4.13%) on September 30, 2024.
- Over the past year, DSGN TTM EBITDA has stayed the same.
- DSGN TTM EBITDA is now -9566.93% below its all-time high of -$623.00 thousand, reached on March 31, 2020.
Performance
DSGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DSGN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.6% | 0.0% | 0.0% |
| 3 y3 years | -832.8% | 0.0% | 0.0% |
| 5 y5 years | -3969.9% | 0.0% | 0.0% |
DSGN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -117.5% | at low | -45.7% | +28.4% | -68.7% | +26.9% |
| 5 y | 5-year | -3969.9% | at low | -2483.2% | +28.4% | -9566.9% | +26.9% |
| alltime | all time | -3969.9% | at low | -2483.2% | +28.4% | -9566.9% | +26.9% |
Design Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.09 M(+8.1%) | -$60.23 M(-4.1%) |
| Jun 2024 | - | -$14.89 M(+4.5%) | -$62.82 M(-10.8%) |
| Mar 2024 | - | -$14.26 M(-4.8%) | -$70.39 M(-9.4%) |
| Dec 2023 | -$77.65 M(+15.6%) | -$14.98 M(-19.8%) | -$77.65 M(-5.2%) |
| Sep 2023 | - | -$18.68 M(-16.8%) | -$81.94 M(-0.5%) |
| Jun 2023 | - | -$22.46 M(+4.4%) | -$82.34 M(+9.2%) |
| Mar 2023 | - | -$21.52 M(+11.7%) | -$75.42 M(+12.3%) |
| Dec 2022 | -$67.19 M | -$19.27 M(+1.0%) | -$67.19 M(+13.9%) |
| Sep 2022 | - | -$19.08 M(+22.8%) | -$58.96 M(+15.2%) |
| Jun 2022 | - | -$15.55 M(+17.0%) | -$51.19 M(+18.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$13.29 M(+20.3%) | -$43.31 M(+21.3%) |
| Dec 2021 | -$35.70 M(+328.9%) | -$11.04 M(-2.3%) | -$35.70 M(+25.2%) |
| Sep 2021 | - | -$11.31 M(+47.3%) | -$28.51 M(+45.6%) |
| Jun 2021 | - | -$7.67 M(+35.2%) | -$19.59 M(+46.4%) |
| Mar 2021 | - | -$5.68 M(+47.2%) | -$13.38 M(+60.7%) |
| Dec 2020 | -$8.32 M(+336.3%) | -$3.86 M(+61.9%) | -$8.32 M(+86.3%) |
| Sep 2020 | - | -$2.38 M(+62.8%) | -$4.47 M(+114.2%) |
| Jun 2020 | - | -$1.46 M(+134.8%) | -$2.09 M(+234.8%) |
| Mar 2020 | - | -$623.00 K | -$623.00 K |
| Dec 2019 | -$1.91 M | - | - |
FAQ
- What is Design Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Design Therapeutics?
- What is Design Therapeutics annual EBITDA year-on-year change?
- What is Design Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Design Therapeutics?
- What is Design Therapeutics quarterly EBITDA year-on-year change?
- What is Design Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Design Therapeutics?
- What is Design Therapeutics TTM EBITDA year-on-year change?
What is Design Therapeutics annual EBITDA?
The current annual EBITDA of DSGN is -$77.65 M
What is the all time high annual EBITDA for Design Therapeutics?
Design Therapeutics all-time high annual EBITDA is -$1.91 M
What is Design Therapeutics annual EBITDA year-on-year change?
Over the past year, DSGN annual EBITDA has changed by -$10.47 M (-15.58%)
What is Design Therapeutics quarterly EBITDA?
The current quarterly EBITDA of DSGN is -$16.09 M
What is the all time high quarterly EBITDA for Design Therapeutics?
Design Therapeutics all-time high quarterly EBITDA is -$623.00 K
What is Design Therapeutics quarterly EBITDA year-on-year change?
Over the past year, DSGN quarterly EBITDA has changed by $0.00 (0.00%)
What is Design Therapeutics TTM EBITDA?
The current TTM EBITDA of DSGN is -$60.23 M
What is the all time high TTM EBITDA for Design Therapeutics?
Design Therapeutics all-time high TTM EBITDA is -$623.00 K
What is Design Therapeutics TTM EBITDA year-on-year change?
Over the past year, DSGN TTM EBITDA has changed by $0.00 (0.00%)